FindTrial
Sign In

Early Phase II clinical study of AK150 for the treatment of knee osteoarthritis

Early Phase II clinical study of AK150 for the treatment of knee osteoarthritis

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221101
Enrollment
Unknown
Registered
2010-05-18
Start date
2010-05-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

investigational material(s) Generic name etc : AK150 INN of investigational material : Therapeutic category code : 114 Antipyretics, analgesics and anti-inflammatory agents Dosage and Administration

Sponsors

ASAHI KASEI PHARMA CORPORATION
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Ambulatory outpatients who do not need a cane or other orthopedic device to enable or assist in motility. (2)Knee pain has experienced (3)Patients should have a 2 - 3 on the Kellgren-Lawrence (K-L) grading scale by X-Ray.

Exclusion criteria

Exclusion criteria: (1) Having undergone some sort of surgical procedure or some other kind of invasive procedure in the evaluated knee. (2) Secondary knee osteoarthritis in the evaluated knee. (3) Intra-articular administration of hyaluronic acid to the evaluated knee within 3 months prior to the start of administration.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026